IL1RL1 and acute myeloid leukemia: We addressed wether IL1RL1 expression is lower in AML of faborable-risk [t(8;21), t(15;17), inv(16)] vs. intermediate-risk (characterized by the absence of favorable or unfavorable cytogenetic and molecular abnormalities) and if IL1RL1 expression would stratify further AML with intermediate-risk.